OncoTelic Overview
- Founded
- 2015
- Status
- Public
- Employees
- 13
- Stock Symbol
- MATN
- Investments
- 1
- Share Price
- $0.22
- (As of Wednesday Closing)
OncoTelic General Information
Description
Mateon Therapeutics Inc is an oncology company focusing on therapies against cancers and infectious diseases. It has three business segments namely, PointR; Mateon/Oxigene; and Oncotelic. PointR is the developer of vision grid/cluster computing/AI to support drug development. Mateon/Oxigene develops a Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma and OXi4503 rare pediatric designation for pediatric ALL. Oncotelic consists development of OT-101 - antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 against pancreatic cancer, glioblastoma, and melanoma. The firm is also developing Artemisinin which is approved by India and in phase 4 clinical trial against COVID.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
- 29397 Agoura Road
- Suite 107
- Agoura Hills, CA 91301
- United States
OncoTelic Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.22 | $0.22 | $0.08 - $0.38 | $19.5M | 89.6M | 323K | -$0.12 |
OncoTelic Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 18,345 | 14,796 | 2,131 | 1,991 |
| Revenue | 1,741 | 0 | 0 | 0 |
| EBITDA | (6,973) | (5,828) | (2,751) | (13,838) |
| Net Income | (9,544) | (6,638) | (2,737) | (13,812) |
| Total Assets | 24,629 | 23,685 | 799 | 1,172 |
| Total Debt | 3,022 | 1,501 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
OncoTelic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore OncoTelic‘s full profile, request access.
Request a free trialOncoTelic Executive Team (11)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Amit Shah | Chief Financial Officer | ||
| Chulho Park Ph.D | Co-Founder & Chief Business Officer | ||
| Frederick Driscoll | Chief Executive Officer & Board Member |
OncoTelic Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anthony Maida Ph.D | Self | Board Member | 000 0000 |
| Frederick Driscoll | Self | Chief Executive Officer & Board Member | 000 0000 |
OncoTelic Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOncoTelic Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 00000000000 | 25-Apr-2019 | 000000000000000000 | Drug Discovery | 00000 00000 00.0 |